npj Breast Cancer

Papers
(The TQCC of npj Breast Cancer is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer351
Triple negative breast cancer: Pitfalls and progress184
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now146
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group126
Immunotherapy in breast cancer: an overview of current strategies and perspectives117
Evolution of HER2-low expression from primary to recurrent breast cancer113
Connected-UNets: a deep learning architecture for breast mass segmentation78
Large language model (ChatGPT) as a support tool for breast tumor board77
Immunotherapy for early triple negative breast cancer: research agenda for the next decade77
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer64
PARP inhibition in breast cancer: progress made and future hopes62
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment58
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer55
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy50
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment47
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma45
Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer44
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer42
Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis41
An emerging generation of endocrine therapies in breast cancer: a clinical perspective40
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL40
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors40
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer39
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies38
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer38
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort37
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer35
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer35
Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge35
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups34
IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer33
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis33
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes32
Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation32
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study32
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis31
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk30
A careful reassessment of anthracycline use in curable breast cancer30
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer30
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression29
Potential of ultra-high-resolution photon-counting CT of bone metastases: initial experiences in breast cancer patients29
The clinical and molecular significance associated with STING signaling in breast cancer27
Deep learning models for histologic grading of breast cancer and association with disease prognosis27
MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis26
Allostatic load: a framework to understand breast cancer outcomes in Black women26
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer26
Oncogene-mediated metabolic gene signature predicts breast cancer outcome26
The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data25
Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway25
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer25
Integrative multiomics-histopathology analysis for breast cancer classification24
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer24
A randomized intervention involving family to improve communication in breast cancer care23
Subclonal heterogeneity and evolution in breast cancer23
How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies22
Effects of systemic inflammation on relapse in early breast cancer22
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity21
Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants21
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer21
Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients21
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer21
Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations21
MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer21
Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites21
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study21
De-escalation in breast cancer surgery20
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer20
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer20
Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome20
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)20
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer20
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE19
Automated percent mammographic density, mammographic texture variation, and risk of breast cancer: a nested case-control study19
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy19
Long non-coding RNA MIR200CHG promotes breast cancer proliferation, invasion, and drug resistance by interacting with and stabilizing YB-119
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer19
Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality19
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes19
Predicting breast cancer types on and beyond molecular level in a multi-modal fashion18
Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours18
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients18
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies18
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness18
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study18
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases18
The human intermediate prolactin receptor is a mammary proto-oncogene18
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer18
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan18
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence18
Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis17
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial17
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer17
Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-617
Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis17
Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women17
Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma16
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing16
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease16
Unmasking the immune microecology of ductal carcinoma in situ with deep learning16
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy16
Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America16
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer16
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 03615
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer15
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer15
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation15
Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance15
Immune landscape of breast tumors with low and intermediate estrogen receptor expression15
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®15
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis15
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis14
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy14
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer14
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB14
Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer14
Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB314
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer14
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab14
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis14
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer14
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ14
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia13
Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery13
Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry13
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells13
Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer13
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ13
Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy13
Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial13
Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology13
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer13
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib13
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer13
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer13
Clinical outcomes of de novo metastatic HER2-low breast cancer: a National Cancer Database Analysis13
0.059808969497681